Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion

References

• al RefaieFNHershkoCHoffbrandAVResults of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron ChelatorsBr J Haematol19959122497577638
   PubMed Web of Science ®Google Scholar
• Apotex2004 Ferriprox package insert
   Google Scholar
• Borgna-PignattiCCappelliniMDDe StefanoPCardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia majorBlood20061073733716373663
   PubMed Web of Science ®Google Scholar
• BrittenhamGMGriffithPMNienhuisAWEfficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia majorN Engl J Med1994331567738047080
   PubMed Web of Science ®Google Scholar
• CabantchikZIBreuerWZanninelliGLPI-labile plasma iron in iron overloadBest Pract Res Clin Haematol2005182778715737890
   PubMed Web of Science ®Google Scholar
• CappelliniMDBejaouiMAgaogluLPatient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy [abstract]Blood20051062704
   Google Scholar
• CappelliniMDCohenAPigaAA Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalas-semiaBlood200610734556216352812
   PubMed Web of Science ®Google Scholar
• CighettiGDucaLBortoneLOxidative status and malondialdehyde in beta-thalassaemia patientsEur J Clin Invest200232Suppl 1556011886433
   PubMed Web of Science ®Google Scholar
• CohenAMaseraGZoumbosNEffect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade®, ICL670) [abstract]Blood2005106822
   Google Scholar
• CunninghamMJMacklinEANeufeldEJComplications of beta-thalassemia major in North AmericaBlood200410434914988152
   PubMed Web of Science ®Google Scholar
• DaarSTaherAPathareADeferasirox (Exjade® ICL 670) provides 24-hour protection from labile plasma iron (LPI), in iron overloaded β-thalassaemia patients previously chelated with mono- or combination therapy [abstract]Haematologica200691Suppl 131
   Google Scholar
• De LucaCFilosaAGrandinettiMBlood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemiaFree Radic Res1999304536210400457
   PubMed Web of Science ®Google Scholar
• EleftheriouPTannerMPennellDResponse of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis [abstract]Haematologica200691Suppl 1999
   Google Scholar
• [EMEA] European Medicines AgencyFerriprox European Public Assessment Report, Scientific Discussion2005 www emea eu int
   Google Scholar
• [Exjade PI] Novartis Pharmaceuticals CorporationExjade (deferasirox) Prescribing information [online]2005 Accessed on 20 February 2007. URL: http://www.exjade.com
   Google Scholar
• ForniGLPigaAGalanelloRGrowth and sexual development in pediatric patients treated over 48 weeks with ICL670, a once-daily oral iron chelator [abstract]Ped Blood Cancer2005441106
   Google Scholar
• GalanelloRPigaAAlbertiDSafety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemiaJ Clin Pharmacol2003435657212817519
   PubMed Web of Science ®Google Scholar
• GalanelloRPigaAForniGLPhase II clinical evaluation of deferasirox (Exjade, ICL670), a once-daily oral chelating agent, in paediatric patients with β-thalassaemia majorHaematologica20069113435117018383
   PubMedGoogle Scholar
• GattermannNCazzolaMGreenbergPThe efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overloadLeuk Res200529Suppl 1S67
   Google Scholar
• GlicksteinHBen ElRShvartsmanMIntracellular labile iron pools as direct targets of iron chelators. A fluorescence study of chelator action in living cellsBlood200510632425016020512
   PubMed Web of Science ®Google Scholar
• GreenbergPDineGGanserADeferasirox (Exjade®, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia [abstract]Blood20051062694
   Google Scholar
• GreenbergPLBaerMRBennettJMMyelodysplastic syndromes clinical practice guidelines in oncologyJ Natl Compr Canc Netw20064587716403405
   PubMedGoogle Scholar
• HershkoCKonijnAMNickHPICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in cultureBlood20019711152211159545
   PubMed Web of Science ®Google Scholar
• HoffbrandAVCohenAHershkoCRole of deferiprone in chelation therapy for transfusional iron overloadBlood2003102172412637334
   PubMed Web of Science ®Google Scholar
• IshizakaNSaitoKMitaniHIron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formationCirculation20021061840612356639
   PubMedGoogle Scholar
• ModellBKhanMDarlisonMSurvival in beta-thalassaemia major in the UK: data from the UK Thalassaemia RegisterLancet20003552051210885361
   PubMed Web of Science ®Google Scholar
• NickHAcklinPLattmannRDevelopment of tridentate iron chelators: from desferrithiocin to ICL670Curr Med Chem20031010657612678677
   PubMed Web of Science ®Google Scholar
• NickHWongAAcklinPICL670A: preclinical profileAdv Exp Med Biol200250918520312572995
   PubMed Web of Science ®Google Scholar
• Nisbet-BrownEOlivieriNFGiardinaPJEffectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialLancet2003361159760212747879
   PubMed Web of Science ®Google Scholar
• OlivieriNFNathanDGMacMillanJHSurvival in medically treated patients with homozygous beta-thalassemiaN Engl J Med199433157488047081
   PubMed Web of Science ®Google Scholar
• PennellDJBerdoukasVKaragiorgaMRandomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood200610737384416352815
   PubMed Web of Science ®Google Scholar
• PigaAGalanelloRForniGLRandomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadHaematologica2006918738016818273
   PubMed Web of Science ®Google Scholar
• PigaAGalanelloRFoschiniMLOnce-daily treatment with the oral iron chelator ICL670 (Exjade®): Results of a Phase II study in pediatric patients with β-thalassemia major [abstract]Blood20041043614
   Google Scholar
• PorterJBorgna-PignattiCBaccaraniMIron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis [abstract]Blood20051062690
   Google Scholar
• PorterJBAbeysingheRDMarshallLKinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapyBlood199688705138695819
   PubMed Web of Science ®Google Scholar
• PorterJBPractical management of iron overloadBr J Haematol2001a1152395211703317
   PubMed Web of Science ®Google Scholar
• PorterJBDeferoxamine pharmacokineticsSemin Hematol2001b3863811206963
   PubMed Web of Science ®Google Scholar
• SteinhauserSHeinzUBartholomaMComplex formation of ICL670 and related ligands with Fe III and Fe IIEur J Inorg Chem200421417792
   Web of Science ®Google Scholar
• TcherniaGVichinskyEJengMThe once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anaemia patientsHaematologica200590Suppl 2192
   Google Scholar
• VichinskyEFischerRFungEA randomized, controlled Phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade®, ICL670) is well tolerated and reduces iron burden [abstract]Blood2005106313
   Google Scholar
• VichinskyEFischerRPakbazZSatisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): comparison between deferasirox (Exjade®, ICL670) and deferoxamine (DFO) [abstract]Blood2005106233415956287
   PubMedGoogle Scholar
• WonkeBClinical management of beta-thalassemia majorSemin Hematol200138350911605170
   PubMed Web of Science ®Google Scholar
• WoodJCOtto-DuesselMGonzalesIICL670 removes cardiac iron in a gerbil model of iron overload [abstract]Blood20051062695
   Google Scholar